Research programme: HBV therapeutics - Kainos Medicine/Institut Pasteur Korea
Latest Information Update: 28 Jul 2024
Price :
$50 *
At a glance
- Originator Institut Pasteur Korea; Kainos Medicines
- Class Antivirals; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in Hepatitis-B in South Korea
- 07 Jul 2022 HBV therapeutics is still in early research for Hepatitis B in South Korea (Kainos Medicines pipeline, July 2022)
- 28 Sep 2020 No recent reports of development identified for research development in Hepatitis-B in South Korea